Related Documents
-
Notice: Agency information collection activities; proposals, submissions, and approvals
45 reads -
Notice: Human drugs:
Drug products withdrawn from sale for reasons other than safety or effectiveness— ACIPHEX (rabeprazol sodium)
73 reads -
Notice: Human drugs:
Drug products withdrawn from sale for reasons other than safety or effectiveness— Animal Drug User Fee Act; performance and reauthorization
37 reads -
Notice: Human drugs:
New drug applications— Penthrane (methoxyflurane) Inhalation Liquid, 99.9 percent; approval withdrawn
98 reads -
Notice: Agency information collection activities; proposals, submissions, and approvals
15 reads -
Notice: Human drugs:
Drug products withdrawn from sale for reasons other than safety or effectiveness— TEQUIN injection, 10 milligrams
67 reads -
Notice: Agency information collection activities; proposals, submissions, and approvals
55 reads -
Notice: Human drugs:
New drug applications— Premarket approval applications; list; safety and effectiveness summaries’ availability
111 reads -
Notice: Meetings: Peripheral and Central Nervous System Drugs Advisory Committee
44 reads -
Notice: Human drugs:
Drug products withdrawn from sale for reasons other than safety or effectiveness— DECADRON tablets
114 reads -
Notice: Harmonisation International Conference; guidelines availability: Biotechnological/biological products; Q5E comparability subject to changes in manufacturing process
80 reads -
Notice: Committees; establishment, renewal, termination, etc.: CollaGenex Pharmaceuticals, Inc., approval withdrawn
71 reads -
Notice: Human drugs:
New drug applications— High Chemical Co., et al. approval withdrawn
34 reads -
Notice: Agency information collection activities; proposals, submissions, and approvals
29 reads -
Notice: Human drugs:
Drug products withdrawn from sale for reasons other than safety or effectiveness— SURPASS
48 reads -
Notice: Agency information collection activities; proposals, submissions, and approvals
22 reads -
Notice: Human drugs:
New drug applications— Industry Exchange Workshop on Food and Drug Administration Clinical Trial Requirements
48 reads -
Notice: Agency information collection activities; proposals, submissions, and approvals
33 reads -
Notice: Agency information collection activities; proposals, submissions, and approvals
15 reads
Related Documents
Flag this document
2 Pages
